• Resources
  • Blog
  • Journalists
  • Log In
  • Sign Up
  • Data Privacy
  • Send a Release
Cision PR Newswire: news distribution, targeting and monitoring home
  • News
  • Products
    • Overview
    • Distribution by PR Newswire
    • Cision Communications Cloud®
    • Cision IR
    • All Products
  • Contact
    • General Inquiries
    • Request a Demo
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices

 

When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • All Products
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • All Products
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR

Thoratec Reports 37 Percent Increase in Annual Revenues From Continuing Operations

Fiscal 2010 GAAP Net Income Per Diluted Share of $0.99

Fiscal 2010 Non-GAAP Net Income Per Diluted Share of $1.23


News provided by

Thoratec Corporation

Jan 27, 2011, 04:02 ET

Share this article

Share this article


PLEASANTON, Calif., Jan. 27, 2011 /PRNewswire/ -- Thoratec Corporation (Nasdaq: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today that revenues from continuing operations in fiscal 2010 increased 37 percent over those in fiscal 2009.

Results from continuing operations for both the full year and fourth quarter of fiscal 2010 and 2009 exclude contributions from the company’s International Technidyne Corporation (ITC) Division. Thoratec completed the divestiture of ITC in November 2010.

For the year ended January 1, 2011, revenues were $383.0 million versus $280.0 million in the prior year. Revenues for the fourth quarter of fiscal 2010 were $97.6 million, an increase of 20 percent over revenues of $81.0 million in the fourth quarter of fiscal 2009.

Net income on a GAAP basis in fiscal 2010 was $59.0 million, or $0.99 per diluted share, versus GAAP net income of $28.9 million, or $0.50 per diluted share, in fiscal 2009. Non-GAAP net income, which is described later in this press release, was $79.8 million, or $1.23 per diluted share, in fiscal 2010, versus non-GAAP net income of $53.8 million, or $0.86 per diluted share, in fiscal 2009.

“This past year was marked by many successes, including FDA approval and launch of the HeartMate II® LVAS (Left Ventricular Assist System) for the Destination Therapy (DT) indication, continued improvements in clinical data in both the Bridge-to-Transplantation (BTT) and DT patient populations, and an impressive financial performance.  We have also implemented a broad range of initiatives designed to further develop the market and advance our leadership position,” said Gary F. Burbach, president and chief executive officer.

“Our financial performance for the year was driven by strong continued adoption of the HeartMate II for DT and BTT in both North America and Europe, and we realized solid operating leverage as evidenced by our earnings growth,” he noted.

The company indicated that it ended 2010 with 254 HeartMate II centers globally, an increase of 43 centers during the year, with 211 centers worldwide now utilizing its new HeartMate peripherals, which are providing important quality of life benefits to patients and generating incremental revenue growth. In addition, there are now 90 centers with CMS (Centers for Medicare and Medicaid Services) certification for reimbursement for DT.

“As we begin 2011, we have a solid foundation upon which to build our business, and with our market development initiatives to drive referrals from cardiologists, facilitate center expansion, increase our international presence and realize continued improvements in patient outcomes, we are optimistic about our ability to achieve significant long-term growth,” Burbach commented.

“Additionally,” Burbach continued, “we have an active product pipeline that includes the continued evolution of the HeartMate II, the development of our next-generation pumps—HeartMate III, HeartMate X and PHP (Percutaneous Heart Pump)—and the introduction of cross-platform breakthrough technologies designed to enhance the HeartMate II, as well as future pump platforms. We believe these market-leading innovations will drive broader adoption of our offerings and enable us to serve an expanded patient population, while resulting in improved patient outcomes and quality of life, less invasive procedures and reduced cost of care,” he said.

FINANCIAL HIGHLIGHTS

Thoratec reported revenues of $383.0 million in 2010 versus revenues of $280.0 million in 2009. The HeartMate product line accounted for $333.1 million in revenues, a 45 percent increase over sales of $229.8 million a year ago. The Thoratec® product line, which includes the PVAD and IVAD, accounted for sales of $29.5 million, a 15 percent decline versus revenues of $34.8 million a year ago. CentriMag® Blood Pump sales in 2010 were $17.7 million, an increase of 41 percent compared to sales of $12.6 million in 2009. The balance of the company’s revenues reflects contribution from its graft business. In 2010, pump sales accounted for $264.3 million, an increase of 29 percent over revenues of $204.6 million a year ago, while non-pump sales accounted for $116.0 million, an increase of 60 percent versus revenue of $72.6 million a year ago. Revenues in North America were $324.3 million, an increase of 38 percent over revenues of $234.2 million a year ago. International revenues in 2010 were $58.7 million, an increase of 28 percent compared to sales of $45.8 million in 2009. Foreign exchange rate fluctuations in 2010 had a $1.4 million unfavorable impact on revenues compared to 2009.

GAAP gross margin in 2010 was 67.7 percent versus 65.9 percent a year ago. Non-GAAP gross margin, which is described later in this press release, was 68.0 percent versus 66.2 percent in 2009. The year-over-year increase in gross margin was due to increased volume and the roll-out of our external peripherals, as well as lower inventory reserves driven by the $6.9 million of HeartMate XVE reserves recorded in 2009.  These benefits were in part offset by increased warranty costs and pump to non-pump mix.

Operating expenses on a GAAP basis in 2010 were $157.8 million versus $134.6 million a year ago. On a non-GAAP basis, operating expenses in 2010 were $136.7 million versus $103.3 million in 2009. Operating expenses on a non-GAAP basis are described later in this press release. The year-over-year increase in operating expenses was due primarily to spending on product and market development initiatives, including sales force expansion and the addition of research and development personnel, as well as the PHP acquisition, which occurred in the first quarter of 2010.

On a GAAP basis, other expense was $8.9 million in 2010 versus other expense of $7.2 million in 2009. On a non-GAAP basis, other expense totaled $672,000 versus other income of $442,000 a year ago. Other income and expense on a non-GAAP basis is described later in this press release.

The company’s GAAP effective tax rate in 2010 was 36.2 percent versus 32.1 percent in 2009. The non-GAAP tax rate, which is described later in this press release, was 35.2 percent in 2010 compared with 34.9 percent in 2009. The increase in the GAAP and non-GAAP effective tax rates was due to higher pre-tax income and return to provision adjustments.

Cash and investments at the end of 2010 were $469.5 million versus $331.6 million at the end of 2009.  The cash balance at the end of fiscal 2010 includes proceeds of $55.0 million from the sale of ITC.

GUIDANCE FOR FISCAL 2011

The following statements are based on current expectations. These statements are forward-looking and actual results may differ materially. For a more detailed discussion of forward-looking statements, please see additional information below.

The company expects revenues will be in the range of $410-$425 million, driven by revenue growth of 10-15 percent for the HeartMate product line. Revenues for other product categories, including the Thoratec line, CentriMag and grafts, are in aggregate expected to decline by approximately 10 percent versus 2010 to approximately $45 million.

Gross margins on a GAAP basis are expected to be approximately 67.5 percent and on a non-GAAP basis gross margins are expected to be approximately 68 percent.

GAAP operating expenses are expected to increase approximately 11 to 12 percent over 2010, while non-GAAP operating expenses are expected to increase approximately 10 percent versus 2010. The projected growth in operating expenses is due primarily to investments in our technology platforms and market expansion activities.

GAAP net income per diluted share is expected to be in the range of $1.02 to $1.12 and non-GAAP net income per diluted share in 2011 is expected to be in the range of $1.35 to $1.45.

CONFERENCE CALL/WEBCAST INFORMATION

Thoratec will hold a conference call to discuss its financial results and operating activities for all interested parties at 1:30 p.m., Pacific Standard Time, (4:30 p.m., Eastern Standard Time) today. The teleconference can be accessed by calling (719) 457-2728, passcode 5849363. Please dial in 10-15 minutes prior to the beginning of the call. The webcast will be available via the Internet at http://www.thoratec.com. A replay of the conference call will be available through Thursday, February 3, via http://www.thoratec.com or by telephone at (719) 457-0820, passcode 5849363.

GAAP TO NON-GAAP RECONCILIATION

Thoratec management evaluates and makes operating decisions using various measures. These measures are generally based on revenues generated by its products and certain costs of producing those revenues, such as costs of product sales, research and development and selling, general and administrative expenses. We use the following measures, which are not calculated in accordance with Generally Accepted Accounting Principles (“GAAP”): non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating expenses, non-GAAP other income and expense,  non-GAAP tax rate, non-GAAP net income, non-GAAP net income per diluted share and non-GAAP shares used to compute diluted net income per share. These are non-GAAP financial measures under Section 101 of Regulation G under the Securities Exchange Act of 1934, as amended. These non-GAAP financial measures are calculated by excluding certain GAAP financial items that we believe have less significance to the day-to-day operation of our business.  The company has outlined below the type and scope of these exclusions and the limitations on the use of the non-GAAP financial measures as a result of these exclusions.

Management uses these non-GAAP financial measures for financial and operational decision making, including in the determination of employee annual cash incentive compensation, as a means to evaluate period-to-period comparisons, as well as comparisons to our competitors’ operating results.  Management also uses this information internally for forecasting and budgeting, as it believes that the measures are indicative of Thoratec core operating results.  Management also believes that non-GAAP financial measures provide useful supplemental information to management and investors regarding the performance of the company’s business operations, provide a greater transparency with respect to key metrics used by management in its decision making, facilitate comparisons of results for current periods and guidance for future periods with our historical operating results, and assist in analyzing future trends.

Non-GAAP net income consists of GAAP net income, excluding, as applicable, the tax effected impact of share-based compensation expense, amortization of purchased intangibles, expenses associated with the retrospective adoption of the accounting for convertible debt instruments that may be settled in cash upon conversion, including partial settlements in accordance with Financial Accounting Standards Board (“FASB”) issued Accounting Standards Codification (“ASC”) 470-20, Debt, HeartWare transaction costs and unrealized losses on the equity conversion option included in the HeartWare loan agreement.

Non-GAAP net income per diluted share is defined as non-GAAP net income divided by the weighted average number of shares on a fully-diluted basis.  

Non-GAAP shares used to compute diluted net income per share consists of GAAP shares used to compute diluted net income per share adjusted for any inclusions made in conjunction with dilutive impact of Thoratec’s convertible debt instruments and any exclusions made in conjunction with the application of the two-class method for calculating net income per share.

Non-GAAP gross profit and gross margin consist of GAAP gross profit and gross margin excluding share-based compensation expense.

Non-GAAP operating expenses consist of GAAP operating expenses excluding share-based compensation expense, amortization of purchased intangibles, and HeartWare transaction costs.

Non-GAAP other income and expense consists of GAAP other income and expenses excluding expenses related to the accounting for convertible debt instruments that may be settled in cash upon conversion, including partial settlements, in accordance with ASC 470-20, Debt and unrealized gains on the equity conversion option included in the HeartWare loan agreement.

Non-GAAP tax expense consists of the GAAP tax expense adjusted for the tax effect of the adjustments from GAAP net income to non-GAAP net income.

Management believes that it is useful in measuring Thoratec’s operations to exclude amortization of intangibles.  These costs are primarily fixed at the time of an acquisition and, unlike other fixed costs that result from ordinary operations, are the result of infrequent and irregular events.

Because of varying valuation methodologies, subjective assumptions and the variety of award types that companies can use, Thoratec management believes that providing non-GAAP financial measures that exclude share-based compensation allows investors to compare Thoratec’s recurring core business operating results to those of other companies and over multiple periods.  The exclusion also enhances investors’ ability to review Thoratec’s business from the same perspective as Thoratec management, which believes that share-based compensation expense is not directly attributable to the underlying performance of the company’s business operations.

Due to the subjective assumptions used to develop non-cash interest expense related to the accounting for convertible debt instruments that may be settled in cash upon conversion, including partial settlements, in accordance with ASC 470-20, Debt, Thoratec management believes that providing non-GAAP financial measures that exclude such expense allows investors to compare Thoratec’s recurring core business operating results to those of other companies and over multiple periods.  The exclusion also enhances investors’ ability to review Thoratec’s business from the same perspective as Thoratec management.

To enable investors to compare Thoratec’s recurring core business operating results to those of other companies and over multiple periods, Thoratec has excluded the HeartWare transaction costs as they are non-recurring in nature.

There are a number of limitations related to the use of non-GAAP financial measures.  First, non-GAAP financial measures exclude some costs, namely share-based compensation, that are recurring expenses.  Second, share-based compensation is part of an employee’s compensation package and as such may be useful for investors to consider.  Third, the components of costs that we exclude in our non-GAAP financial measures calculations may differ from components that our peer companies exclude when they report their results from operations.

Non-GAAP financial measures should not be considered as a substitute for measures of financial performance in accordance with GAAP. However, these measures may provide additional insight into Thoratec’s financial results. Investors and potential investors are strongly encouraged to review the reconciliation of non-GAAP financial measures contained within this press release with their most directly comparable GAAP financial results and not to rely on any single financial measure to evaluate our business.

The reconciliations of the forward looking non-GAAP financial measures to the most directly comparable GAAP financial measures in the tables below include all information reasonably available to Thoratec at the date of this press release.  These tables include adjustments that we can reasonably predict.  Events that could cause the reconciliation to change include acquisitions and divestitures of business, goodwill and other asset impairments and sales of marketable equity securities.

The following table includes the GAAP income statement for continuing operations for the three and twelve month periods ending 2010 and 2009:

THORATEC CORPORATION

Condensed Consolidated Statements of Continuing Operations

(Unaudited)

(in thousands, except for per share data)





















Three Months Ended


Twelve Months Ended



January 1, 2011


January 2, 2010


January 1, 2011


January 2, 2010






Product sales


$        97,607


$       81,003


$     382,973


$    279,968

Cost of product sales


32,938


28,528


123,709


95,555

Gross profit


64,669


52,475


259,264


184,413

Operating expenses:









Selling, general and administrative


25,212


19,454


89,222


82,079

Research and development


14,696


11,038


58,831


42,743

Amortization of purchased intangible assets


2,446


2,393


9,772


9,834

Total operating expenses


42,354


32,885


157,825


134,656

Income from operations


22,315


19,590


101,439


49,757

Other income and (expense):









Interest expense


(3,047)


(3,140)


(12,327)


(12,307)

Interest income and other


1,174


(4,158)


5,435


5,146

Impairment on strategic investment


57


-


(2,000)


-

Income before income taxes


20,499


12,292


92,547


42,596

Income tax expense


(7,875)


(4,219)


(33,542)


(13,691)










Net income from continuing operations


$        12,624


$         8,073


$       59,005


$      28,905



















Net income per share from continuing operations









Basic


$            0.22


$           0.14


$          1.02


$          0.51

Diluted


$            0.21


$           0.14


$          0.99


$          0.50










Shares used to compute net income per share from continuing operations:









Basic


58,257


56,300


57,670


55,910

Diluted


59,298


57,750


59,071


57,322

The following table presents our quarterly and full year revenues from continuing operations by source for fiscal 2010 and fiscal 2009:

THORATEC CORPORATION

Quarterly Revenue Analysis from Continuing Operations

(Unaudited)

(in millions)












Three Months Ended


Twelve Months Ended


April 3, 2010


July 3, 2010


October 2, 2010


January 1, 2011


January 1, 2011





Revenue by Product Line










HeartMate

$          86.1


$          82.5


$          80.6


$          83.9


$         333.1

PVAD & IVAD

8.8


7.3


6.2


7.2


29.5

CentriMag

3.7


4.6


3.7


5.7


17.7

Other

0.7


0.7


0.5


0.8


2.7

Total

$          99.3


$          95.1


$          91.0


$          97.6


$         383.0











Revenue by Category










Pump

$          69.5


$          64.4


$          62.6


$          67.8


$         264.3

Non-Pump

29.1


30.0


27.9


29.0


116.0

Other

0.7


0.7


0.5


0.8


2.7

Total

$          99.3


$          95.1


$          91.0


$          97.6


$         383.0











Revenue by Geography










North America

$          84.0


$          81.9


$          78.5


$          79.9


$         324.3

International

15.3


13.2


12.5


17.7


58.7

Total

$          99.3


$          95.1


$          91.0


$          97.6


$         383.0
































Three Months Ended


Twelve Months Ended


April 4, 2009


July 4, 2009


October 3, 2009


January 2, 2010


January 2, 2010











Revenue by Product Line










HeartMate

$          51.8


$          57.1


$          54.1


$          66.8


$         229.8

PVAD & IVAD

9.5


8.4


7.9


9.0


34.8

CentriMag

2.6


3.1


2.5


4.4


12.6

Other

0.7


0.6


0.7


0.8


2.8

Total

$          64.6


$          69.2


$          65.2


$          81.0


$         280.0











Revenue by Category










Pump

$          50.4


$          53.8


$          47.6


$          52.8


$         204.6

Non-Pump

13.5


14.8


16.9


27.4


72.6

Other

0.7


0.6


0.7


0.8


2.8

Total

$          64.6


$          69.2


$          65.2


$          81.0


$         280.0











Revenue by Geography










North America

$          53.9


$          58.3


$          54.4


$          67.6


$         234.2

International

10.7


10.9


10.8


13.4


45.8

Total

$          64.6


$          69.2


$          65.2


$          81.0


$         280.0











The following table reconciles the specific items excluded from GAAP net income from continuing operations in the calculation of non-GAAP net income from continuing operations and diluted net income per share from continuing operations for the periods shown below:

THORATEC CORPORATION


Reconciliation of GAAP to Non-GAAP Net Income from Continuing Operations


(Unaudited)


(in thousands, except for per share data)














Three Months Ended


Twelve Months Ended


Net income reconciliation


January 1, 2011


January 2, 2010


January 1, 2011


January 2, 2010










Net income from continuing operations on a GAAP basis


$              12,624


$              8,073


$              59,005


$              28,905


Share-based compensation expense:










- Cost of product sales


314


256


1,262


1,045


- Selling, general and administrative


1,990


1,516


8,064


6,670


- Research and development


726


583


3,328


2,574


Amortization of purchased intangibles


2,446


2,394


9,772


9,833


HeartWare transaction costs


-


1


-


12,314


Impact of ASC 470-20


2,053


1,944


8,220


7,603


Unrealized loss on embedded derivative instrument on HeartWare loan


-


5,240


-


-


Income tax effect of non-GAAP income before tax


839


(460)


1,255


(2,274)


Income tax effect of non-GAAP adjustments


(2,892)


(4,097)


(11,108)


(12,869)


Net income from continuing operations on a non-GAAP basis


$              18,100


$            15,450


$              79,798


$              53,801














Three Months Ended


Twelve Months Ended


Diluted net income from continuing operations per share reconciliation


January 1, 2011


January 2, 2010


January 1, 2011


January 2, 2010










Diluted net income from continuing operations per share on a GAAP basis


$                  0.21


$                0.14


$                  0.99


$                  0.50


Share-based compensation expense:










- Cost of product sales


0.01


-


0.02


0.02


- Selling, general and administrative


0.04


0.02


0.14


0.12


- Research and development


0.01


0.01


0.06


0.04


Amortization of purchased intangibles


0.04


0.04


0.17


0.17


HeartWare transaction costs


-


-


-


0.21


Impact of ASC 470-20


0.04


0.03


0.14


0.13


Unrealized loss on embedded derivative instrument on HeartWare loan


-


0.09


-


-


Income tax effect of non-GAAP income before tax


0.01


-


0.02


(0.04)


Income tax effect of non-GAAP adjustments


(0.05)


(0.07)


(0.19)


(0.21)


Convertible debt dilution and two-class method impact


(0.03)


(0.02)

(1)

(0.12)


(0.08)

(1)

Diluted net income from continuing operations per share on a non-GAAP basis


$                  0.28


$                0.24


$                  1.23


$                  0.86














Three Months Ended


Twelve Months Ended




January 1, 2011


January 2, 2010


January 1, 2011


January 2, 2010


Shares used to compute diluted net income from continuing operations per share reconciliation




















Shares used in calculation of diluted net income per share --GAAP


59,298


57,750


59,071


57,322


Convertible debt dilution impact (1)


7,171


7,290


7,194


7,290


Weighted average unvested restricted stock awards (2)


268


624


357


705


Shares used in calculation of diluted net income from continuing operations per share -- non-GAAP


66,737


65,664


66,622


65,317























(1) The company's total diluted share count on a non-GAAP basis for the three and twelve months ended January 1, 2011 included approximately 7.2 million shares

     underlying its convertible notes as they were dilutive for the respective periods. The company's total diluted share count on a non-GAAP basis for the three and


     twelve months ended January 2, 2010 included approximately 7.3 million shares underlying its convertible notes as they were dilutive for the respective periods.











(2) The company adopted the two-class method in calculating net income per share on a GAAP basis, which excludes the weighted average unvested restricted stock

    awards outstanding of 267,578 and 624,268 for the three months ended January 1, 2011 and January 2, 2010, respectively, and 356,966 and 704,673 for the twelve

    months ended January 1, 2011 and January 2, 2010, respectively.

The following table reconciles the specific items excluded from GAAP gross profit and gross margin from continuing operations in the calculation of non-GAAP gross profit and gross margin from continuing operations for the periods shown below:

THORATEC CORPORATION

Reconciliation of GAAP to Non-GAAP Gross Profit from Continuing Operations

(Unaudited)

(in thousands)












Three Months Ended



Twelve Months Ended



January 1, 2011


January 2, 2010



January 1, 2011


January 2, 2010












Gross profit from continuing operations on a GAAP basis

$        64,669

66.3%

$          52,475

64.8%


$          259,264

67.7%

$            184,413

65.9%

Share-based compensation expense

314


256



1,262


1,045


Gross profit from continuing operations on a non-GAAP basis

$        64,983

66.6%

$          52,731

65.1%


$          260,526

68.0%

$            185,458

66.2%





















The following table reconciles the specific items excluded from GAAP operating expenses from continuing operations in the calculation of non-GAAP operating expenses from continuing operations for the periods shown below:

THORATEC CORPORATION

Reconciliation of GAAP to Non-GAAP Operating Expenses from Continuing Operations

(Unaudited)

(in thousands)










Three Months Ended


Twelve Months Ended


January 1, 2011


January 2, 2010


January 1, 2011


January 2, 2010









Operating expenses from continuing operations on a GAAP basis

$              42,354


$              32,885


$           157,825


$            134,656

Share-based compensation expense:








- Selling, general and administrative

(1,990)


(1,516)


(8,064)


(6,670)

- Research and development

(726)


(583)


(3,328)


(2,574)

Amortization of purchased intangibles

(2,446)


(2,394)


(9,772)


(9,833)

HeartWare transaction costs

-


(1)


-


(12,314)

Operating expenses from continuing operations on a non-GAAP basis 

$              37,192


$              28,391


$           136,661


$             103,265

















The following table reconciles the specific items excluded from GAAP other income and expense from continuing operations in the calculation of non-GAAP other income and expense from continuing operations for the periods shown below:










THORATEC CORPORATION

Reconciliation of GAAP to Non-GAAP Other Income and Expense from Continuing Operations

(Unaudited)

(in thousands)












Three Months Ended


Twelve Months Ended



January 1, 2011


January 2, 2010


January 1, 2011


January 2, 2010










Other income (expense) from continuing operations on a GAAP basis


$           (1,816)


$               (7,298)


$              (8,892)


$               (7,161)

Impact of ASC 470-20


2,053


1,944


8,220


7,603

Unrealized loss on embedded derivative instrument on HeartWare loan


-


5,240


-


-

Other income (expense) from continuing operations on a non-GAAP basis


$               237


$                  (114)


$                 (672)


$                   442










The following table reconciles the GAAP tax expense adjusted for the tax effect of the adjustments from GAAP net income from continuing operations to non-GAAP net income from continuing operations:

THORATEC CORPORATION


Reconciliation of GAAP to Non-GAAP Tax Expense from Continuing Operations


(Unaudited)


(in thousands)













Three Months Ended



Twelve Months Ended



January 1, 2011


January 2, 2010



January 1, 2011


January 2, 2010












Tax expense from continuing operations on a GAAP basis

$             (7,875)

38.4%

$                (4,219)

34.3%


$          (33,542)

36.2%

$           (13,691)

32.1%

Share-based compensation expense and other

(1,328)


(1,347)



(5,342)


(3,892)


Amortization of purchased intangibles

(978)


(958)



(3,909)


(3,934)


HeartWare transaction costs

-


-



-


(4,926)


Impact of adoption of ASC 470-20

(821)


(806)



(3,288)


(3,041)


Unrealized loss on embedded derivative instrument on HeartWare loan

-


(2,096)



-


-


Excess compensation limitations

1,074


649



2,684


649


Tax expense from continuing operations on a non-GAAP basis

$             (9,928)

35.4%

$                (8,777)

36.2%


$          (43,397)

35.2%

$           (28,835)

34.9%





















The following table reconciles the guidance on a GAAP and non-GAAP basis from continuing operations for the periods shown below:

THORATEC CORPORATION

Reconciliation of GAAP to Non-GAAP  Forward-Looking Guidance

(Unaudited)

(in thousands, except for per share data)






Gross margin

For the Fiscal Year Ended 2011



From


To







Gross margin on a GAAP basis

67.50%


67.50%


Share-based compensation expense

0.50%


0.50%


Gross margin on a non-GAAP basis

68.00%


68.00%












Operating expenses growth

For the Fiscal Year Ended 2011



From


To







Increase in operating expense on a GAAP basis

11.00%


12.00%


Share-based compensation expense

-1.00%


-2.00%


Increase in operating expense on a non-GAAP basis

10.00%


10.00%












Net income per diluted share reconciliation

For the Fiscal Year Ended 2011



From


To







Net income per diluted share on a GAAP basis

$                  1.02


$                   1.12


Share-based compensation expense

0.19


0.19


Amortization of purchased intangibles

0.09


0.09


Impact of adoption of ASC 470-20

0.03


0.03


Income tax effect of non-GAAP income before tax

0.02


0.02


Net income per diluted share on a non-GAAP basis

$                  1.35


$                   1.45







Shares used  in calculation of net income per diluted share --GAAP and non-GAAP

63,000


63,000












Thoratec is a world leader in therapies to address advanced-stage heart failure. The company’s products include the HeartMate LVAS and Thoratec® VAD (Ventricular Assist Device) with more than 15,000 devices implanted in patients suffering from heart failure. Thoratec is headquartered in Pleasanton, California. For more information, visit the company’s web site at http://www.thoratec.com.

Thoratec, the Thoratec logo, HeartMate and HeartMate II are registered trademarks of Thoratec Corporation and IVAD is a trademark of Thoratec Corporation.  CentriMag is a registered trademark of Levitronix LLC.

SOURCE Thoratec Corporation

Modal title

Contact Cision

  • Cision Distribution 888-776-0942
    from 8 AM - 9 PM ET

  • Chat with an Expert
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • Cision Communication Cloud®
  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • For Small Business
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • COVID-19 Resources
  • Accessibility Statement
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom

My Services

  • All New Releases
  • Online Member Center
  • ProfNet

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2022 Cision US Inc.